Chardan Capital Raises Earnings Estimates for Immuneering

Immuneering Co. (NASDAQ:IMRX) – Stock analysts at Chardan Capital upped their FY2025 earnings estimates for Immuneering in a report issued on Tuesday, May 6th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($1.36) for the year, up from their prior forecast of ($1.65). Chardan Capital currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.86) per share. Chardan Capital also issued estimates for Immuneering’s FY2026 earnings at ($0.54) EPS.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01).

IMRX has been the subject of several other research reports. Oppenheimer lowered their target price on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of Immuneering in a research report on Thursday, April 10th.

Immuneering Trading Down 4.2 %

NASDAQ IMRX opened at $1.14 on Friday. The business has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $1.79. Immuneering has a 12 month low of $1.00 and a 12 month high of $3.83. The firm has a market capitalization of $41.02 million, a P/E ratio of -0.58 and a beta of -0.22.

Institutional Trading of Immuneering

Large investors have recently added to or reduced their stakes in the stock. Tang Capital Management LLC bought a new position in shares of Immuneering during the 4th quarter valued at approximately $27,000. Marshall Wace LLP purchased a new position in Immuneering in the fourth quarter valued at approximately $47,000. First Manhattan CO. LLC. bought a new position in Immuneering during the fourth quarter valued at $71,000. XTX Topco Ltd increased its position in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after buying an additional 20,871 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of Immuneering by 25.0% in the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after buying an additional 10,126 shares during the period. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.